Patients with non-small cell lung cancer survive longer when their therapy includes durvalumab following platinum-based chemoradiotherapy, reports a new study. The findings of the study are published in the iNew England Journal of Medicine/i.
Durvalumab (Imfinzi (Regd) ) is an immune checkpoint inhibitor that received United States Food and Drug Administration (FDA) approval in February as a new standard-of-care option for patients with stage 3 non-small cell lung cancer where surgery is not an ...
Patients with non-small cell lung cancer survive longer when their therapy includes durvalumab following platinum-based chemoradiotherapy, reports a new study. The findings of the study are published in the iNew England Journal of Medicine/i.
Durvalumab (Imfinzi (Regd) ) is an immune checkpoint inhibitor that received United States Food and Drug Administration (FDA) approval in February as a new standard-of-care option for patients with stage 3 non-small cell lung cancer where surgery is not an ...